quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:15:10·10d
SECFiling
Boundless Bio Inc. logo

Boundless Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

BOLD· Boundless Bio Inc.
Health Care
Original source

Companies

  • BOLD
    Boundless Bio Inc.
    Health Care

Recent analyst ratings

  • Jun 2UpdateH.C. Wainwright$5.00
  • May 28UpdateLeerink Partners$3.00
  • Dec 13UpdateGuggenheim-

Related

  • PR6d
    Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
  • PR37d
    Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
  • SEC46d
    SEC Form 10-K filed by Boundless Bio Inc.
  • SEC46d
    Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
  • PR46d
    Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
  • PR51d
    Boundless Bio to Participate in the Leerink Global Healthcare Conference
  • PR52d
    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
  • SEC77d
    Amendment: SEC Form SCHEDULE 13G/A filed by Boundless Bio Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022